Trial reportEBioMedicine2021
Outcomes of a smartphone-based application with live health-coaching post-percutaneous coronary intervention.
Trial report in EBioMedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03416920 (A Smartphone-based Application Post-myocardial Infarction to Manage Cardiovascular Disease Risk), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Smartphone-based Application Post-myocardial Infarction to Manage Cardiovascular Disease Risk
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Article
- Digital Therapeutics in Cardiovascular Healthcare: A Narrative Review.Current cardiology reports · 2025Review
- Identifying mobile health interventions for post-discharge stroke and myocardial infarction patients: a scoping review.BMJ open · 2025Article
- Review
- Methodological approaches and author-reported limitations in evaluation studies of digital health technologies (DHT): A scoping review of DHT interventions for cancer, diabetes mellitus, and cardiovascular diseases.PLOS digital health · 2025Review
- Alternative Models of Cardiac Rehabilitation to Promote Secondary Prevention in Patients With Coronary Heart Disease After Percutaneous Coronary Intervention: A Scoping Review.The Journal of cardiovascular nursing · 2025Article
- Platform-Based Patient-Clinician Digital Health Interventions for Care Transitions: Scoping Review.Journal of medical Internet research · 2024Article
- Improving transitional care after acute myocardial infarction: A scoping review.Health care science · 2024Article
- Digital tools in cardiac reperfusion pathways: A systematic review.Future healthcare journal · 2024Article
- Impact of AfterAMI Mobile App on Quality of Life, Depression, Stress and Anxiety in Patients with Coronary Artery Disease: Open Label, Randomized Trial.Life (Basel, Switzerland) · 2023Article
- Frontiers and hotspots evolution in anti-inflammatory studies for coronary heart disease: A bibliometric analysis of 1990-2022.Frontiers in cardiovascular medicine · 2023Article
- High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S.Journal of the American College of Cardiology · 2022Article
- Patient Perception When Transitioning from Classic to Remote Assisted Cardiac Rehabilitation.Diagnostics (Basel, Switzerland) · 2022Article
- Predicting the Risk of Unplanned Readmission at 30 Days After PCI: Development and Validation of a New Predictive Nomogram.Clinical interventions in aging · 2022Article
- Prospects of e-Coaching as a Platform for Empowering Families of Person With Mental Disorder: A Qualitative Study.SAGE open nursingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundThe interval between inpatient hospitalization for symptomatic coronary artery disease (CAD) and post-discharge office consultation is a vulnerable period for adverse events.
methodsContent was customized on a smartphone app-based platform for hospitalized patients receiving percutaneous coronary intervention (PCI) which included education, tracking, reminders and live health coaches. We conducted a single-arm open-label pilot study of the app at two academic medical centers in a single health system, with subjects enrolled 02/2018-05/2019 and 1:3 propensity-matched historical controls from 01/2015-12/2017. To evaluate feasibility and efficacy, we assessed 30-day hospital readmission (primary), outpatient cardiovascular follow-up, and cardiac rehabilitation (CR) enrollment as recorded in the health system. Outcomes were assessed by Cox Proportional Hazards model.
findings118 of 324 eligible (36·4%) 21-85 year-old patients who underwent PCI for symptomatic CAD who owned a smartphone or tablet enrolled. Mean age was 62.5 (9·7) years, 87 (73·7%) were male, 40 of 118 (33·9%) had type 2 diabetes mellitus, 68 (57·6%) enrolled underwent PCI for MI and 59 (50·0%) had previously known CAD; demographics were similar among matched historical controls. No significant difference existed in all-cause readmission within 30 days (8·5% app vs 9·6% control, ARR -1.1% absolute difference, 95% CI -7·1-4·8, p = 0·699) or 90 days (16·1% app vs 19·5% control, p = 0.394). Rates of both 90-day CR enrollment (HR 1·99, 95% CI 1·30-3·06) and 1-month cardiovascular follow up (HR 1·83, 95% CI 1·43-2·34) were greater with the app. Weekly engagement at 30- and 90-days, as measured by percentage of weeks with at least one day of completion of tasks, was mean (SD) 73·5% (33·9%) and 63·5% (40·3%). Spearman correlation analyses indicated similar engagement across age, sex, and cardiovascular risk factors. INTERPRETATIONS: A post-PCI smartphone app with live health coaches yielded similarly high engagement across demographics and safely increased attendance in cardiac rehabilitation. Larger prospective randomized controlled trials are necessary to test whether this app improves cardiovascular outcomes following PCI.
fundingNational Institutes of Health, Boston Scientific. CLINICAL
trial registrationNCT03416920 (https://clinicaltrials.gov/ct2/show/NCT03416920).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.